IDT Biologika Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • IDT Biologika's estimated annual revenue is currently $42.6M per year.(i)
  • IDT Biologika's estimated revenue per employee is $201,000

Employee Data

  • IDT Biologika has 212 Employees.(i)

IDT Biologika's People

NameTitleEmail/Phone
1
EVP - General CounselReveal Email/Phone
2
Director Process DevelopmentReveal Email/Phone
3
Director, Human ResourcesReveal Email/Phone
4
Director Business DevelopmentReveal Email/Phone
5
SVP/Managing Director, IDT Biologika CorporationReveal Email/Phone
6
Director Manufacturing and Technical OperationsReveal Email/Phone
7
Sr. QA ManagerReveal Email/Phone
8
Manager Materials ManagementReveal Email/Phone
9
Project ManagerReveal Email/Phone
10
Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M35-3%N/AN/A
#2
$7.2M36-5%N/AN/A
#3
$10.5M52-9%N/AN/A
#4
$344.1M17129%N/AN/A
#5
$27.5M1376%N/AN/A
#6
$107.3M5349%N/AN/A
#7
$12.9M6428%N/AN/A
#8
$31.6M1571%N/AN/A
#9
$31.4M1567%N/AN/A
#10
$11.5M5730%N/AN/A
Add Company

What Is IDT Biologika?

IDT Biologika is an innovative privately-held company with more than 90 years of experience in research, development, manufacture and distribution of biologics for the global protection of human and animal health. With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply. Recognized for its technically sophisticated development, manufacture and handling of biopharmaceuticals and lyophilized compounds in EMA- and FDA-inspected facilities, IDT Biologika has developed into one of the world's leading pharmaceutical and biotechnological companies with a focus on three core areas: animal health, vaccines and pharmaceuticals. In 2013, IDT Biologika achieved sales of approximately €151 million, employing 1,250 employees. Operationally, in Denmark, the Netherlands, Belgium, France and Spain, IDT runs distribution branches whose activities are focused primarily on the animal health business segment. Contract manufacturing services for human pharmaceuticals and vaccines are provided worldwide. In the United States, IDT Biologika Corp. is responsible for sales activities throughout North America. The company's production facilities are located in the BioPharmaPark of Dessau-Rosslau and the Riems district of Greifswald, Germany. IDT Biologika is a member of the Klocke Holding Group. https://idt-biologika.com/en/imprint

keywords:N/A

N/A

Total Funding

212

Number of Employees

$42.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

IDT Biologika News

2022-04-20 - Vaccine Contract Manufacturing Market Size, Scope And Outlook ...

Merck KGaA, Lonza, IDT Biologika GmbH, FUJIFILM Diosynth Biotechnologies U.S.A. Cytovance Biologics, Catalent Ajinomoto Althea Albany Molecular Research PRA...

2022-04-19 - Commercial Aquaculture Vaccines Market Scope and overview, To ...

IDT Biologika GmbH (Ridgeway Biologicals Ltd), MARINNOVAC (AQUATRECK ANIMAL HEALTH S.L.), Ceva Biovac, Zoetis (PHARMAQAS), Vaxxinova,...

2022-04-19 - Animal Vaccines Market Size, Outlook And Forecast | Zoetis, Merck ...

... Merck Animal Health, Boehringer Ingelheim, Elanco, Virbac, Vetoquinol, Phibro Animal Health, Hester Biosciences, Hipra, IDT Biologika.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.3M2127%N/A
#2
$33.9M2205%N/A
#3
$43.6M220N/AN/A
#4
$36.5M221-1%N/A
#5
$32.5M22610%N/A